Abstract
Children and adolescents with bipolar disorder are also at high risk of having comorbid attention-deficit hyperactivity disorder (ADHD). The objective of this study was to estimate improvement in ADHD symptoms in children with bipolar disorder. This was an open-label, study of risperidone monotherapy for the treatment of pediatric bipolar disorder. Thirty-one children and adolescents 4-15 years of age (7.2 +/- 2.8 years) of both sexes (71%, N = 22 male) with pediatric bipolar disorder (YMRS score = 32.9 +/- 8.8) and ADHD (ADHD-RS score = 37.9 +/- 8.9) were included in these analyses. Improvement in ADHD symptoms was contingent on improvement in manic symptoms. Although both hyperactive/impulsive (-7.5 +/- 5.5.6, p < 0.05) and inattentive (-6.8 +/- 5.0, p < 0.05) ADHD symptoms were significantly improved with risperidone, improvement was modest, and only 29% of subjects (N = 6) showed a 30% reduction in ADHD rating scale scores and had a CGI-I </= 2. These results suggest that that treatment with risperidone is associated with tangible but generally modest improvement of symptoms of ADHD in children with bipolar disorder.
References
Nov 1, 1978·The British Journal of Psychiatry : the Journal of Mental Science·R C YoungD A Meyer
Jan 1, 1995·Child Psychiatry and Human Development·C M Borchardt, G A Bernstein
Jun 1, 1995·Journal of the American Academy of Child and Adolescent Psychiatry·M StroberM DeAntonio
Jul 1, 1995·Journal of the American Academy of Child and Adolescent Psychiatry·J WozniakD Mennin
Aug 18, 1995·Journal of Affective Disorders·B GellerM Williams
Sep 18, 1997·Journal of the American Academy of Child and Adolescent Psychiatry·B Geller, J Luby
Nov 1, 1995·Harvard Review of Psychiatry·G L FaeddaD S Lipschitz
Jan 12, 2000·Journal of Child and Adolescent Psychopharmacology·J BiedermanS V Faraone
Jan 19, 2000·Journal of the American Academy of Child and Adolescent Psychiatry·P J Ambrosini
Oct 6, 2000·Biological Psychiatry·J BiedermanJ Wozniak
Jun 4, 2002·The American Journal of Psychiatry·Barbara GellerBetsy Zimerman
Oct 31, 2002·Journal of Clinical Child and Adolescent Psychology : the Official Journal for the Society of Clinical Child and Adolescent Psychology, American Psychological Association, Division 53·Eric A YoungstromJoseph R Calabrese
Aug 21, 2004·Journal of Child and Adolescent Psychopharmacology·Michael G AmanAtilla Turgay
Dec 2, 2004·Journal of Affective Disorders·Joseph BiedermanMegan Aleardi
May 25, 2005·Journal of Child and Adolescent Psychopharmacology·Joseph BiedermanStephen V Faraone
Jul 22, 2005·Journal of the American Academy of Child and Adolescent Psychiatry·Alceu Gomes Correia FilhoLuis Augusto Rohde
Oct 22, 2005·Biological Psychiatry·Joseph BiedermanJanet Wozniak
Nov 26, 2005·Primary Care Companion to the Journal of Clinical Psychiatry·Valsamma Eapen, A K Gururaj
Citations
Jun 21, 2011·Journal of Psychiatric Research·Janet WozniakJoseph Biederman
Sep 30, 2010·BMC Psychiatry·Julia J RucklidgeBonnie J Kaplan
Dec 30, 2014·Journal of Affective Disorders·Álvaro FríasNúria Farriols
May 5, 2016·Journal of Advanced Pharmaceutical Technology & Research·Parvin SafaviMaryam AmirAhmadi
Jun 21, 2015·Child and Adolescent Psychiatric Clinics of North America·Andrea S Young, Mary A Fristad
May 25, 2010·Journal of Attention Disorders·Paulo A GrazianoAyesha S Lall
Feb 20, 2010·Journal of Child and Adolescent Psychopharmacology·Gagan JoshiJoseph Biederman
Feb 20, 2010·Journal of Child and Adolescent Psychopharmacology·Michael KoelchJoerg M Fegert
Feb 12, 2013·Psychopharmacology·Gagan JoshiJoseph Biederman
May 10, 2012·Current Opinion in Psychiatry·Philip Hazell, Rajeev Jairam
Jun 7, 2014·Journal of Child Psychology and Psychiatry, and Allied Disciplines·Covadonga M Díaz-CanejaDolores Moreno
Nov 28, 2008·Annual Review of Psychology·W Andrew CollinsWyndol Furman
May 8, 2010·CNS Spectrums·Julia J Rucklidge, Rachel Harrison
Jul 1, 2010·Expert Review of Neurotherapeutics·Vanya Hamrin, Joanne DeSanto Iennaco
May 29, 2013·Current Psychiatry Reports·Caroly Pataki, Gabrielle A Carlson
Sep 8, 2020·Expert Opinion on Drug Safety·Felice IasevoliAndrea de Bartolomeis